



# Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD 0100)

NIDA RDD 0100 is a research study with two different phases, a Retention Phase and a Discontinuation Phase, at the University of New Mexico Addiction and Substance Abuse Program (ASAP) Primary Care Clinic.

## Retention Phase

### What is the Retention Phase?

This phase will test strategies to improve retention in medication assisted treatment for opioid use disorder. Participants will choose buprenorphine or naltrexone (XR-NTX). Participants will be in medical management, and some will be randomized to using a mHealth app (PEAR-002a; commercial product: ReSET-O).

### Who can participate?

Adults meeting the following criteria:

- OUD
- Willing to choose between BUP or XR-NTX
- Prescribed BUP for less than 10 days or prescribed XR-NTX for less than 28 days
- If choosing BUP, willing to be randomized to SL-BUP or XR-BUP
- In “good enough health”
- Willing to be randomized to MAT with or without mHealth app
- If applicable, effective birth control use

### Benefits:

- Compensation
- Study-provided medication for up to 74 weeks

## Discontinuation Phase

### What is the Discontinuation Phase?

This phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue. Participants will be in medical management and some will be randomized to using a mHealth app (CONNECTIONS).

★ **No active recruitment**

### Who can participate?

Adults meeting the following criteria:

- Taken BUP for at least 1 year or XR-NTX for at least 6 months
- Desire to discontinue MAT
- Stable
- No AUD
- If on BUP, willing to be randomized to taper with SL-BUP or XR-BUP
- Willing to be randomized to MAT with or without mHealth app
- If applicable, effective birth control use

### Benefits:

- Compensation

**Principal Investigator:**  
**Snehal Bhatt**

**Node Coordinator:**  
**Annemarie Madaras**

**Research Coordinator:**  
**Cade Arnink**

**Medical Clinicians:**  
**Vanessa Jacobsohn**  
**Shashwat Pandhi**  
**Brandon Warrick**  
**Sergio Huerta**

**Quality Assurance:**  
**Roberta Chavez**

**Research Assistant:**  
**Fletcher Herring**